Izotropic (IZO) Price & Analysis

Compare

15 Followers

IZO Stock Chart & Stats

C$0.28

C$0.01(8.33%)

At close: Jan 08 4:00 PM EST

C$0.28

C$0.01(8.33%)

Day’s Range― - ―

52-Week RangeC$0.19 - C$0.49

Previous CloseN/A

Volume236.24K

Average Volume (3M)43.33K

Market Cap

C$14.91M

Enterprise ValueC$17.65M

Total Cash (Recent Filing)C$229.86K

Total Debt (Recent Filing)C$2.97M

Price to Earnings (P/E)―

Beta0.01

Next Earnings

Mar 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding67,784,676

10 Day Avg. Volume24,438

30 Day Avg. Volume43,328

Financial Highlights & Ratios

PEG Ratio-0.05

Price to Book (P/B)-2.90

Price to Sales (P/S)0.00

P/FCF Ratio-22.10

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Product SpecializationIzotropic’s focused product strategy—developing a dedicated breast CT platform—creates a durable business model centered on a defined clinical application. Specialization can enable deeper clinical validation, tailored sales channels and differentiation versus general imaging vendors, supporting long-term adoption pathways.

Clinical Use CasePositioning the IzoView system for breast cancer screening and diagnostics targets a stable, ongoing clinical need. A device that provides 3D breast imaging addresses structural demand for improved diagnostic accuracy and can create sustained demand from hospitals and imaging centers if clinical and reimbursement pathways are secured.

Improving Burn RateAn improving TTM free cash flow growth rate indicates management has begun to reduce cash burn and improve capital efficiency. While cash flow remains negative, a durable trend of lower burn can extend runway, reduce near-term financing pressure and signal operational progress in advancing toward commercialization milestones.

Bears Say

No RevenueThe absence of any reported revenue demonstrates the company has not yet commercialized its technology at scale. Persisting operating losses mean the business model’s ability to generate sustainable, recurring cash flow is unproven, increasing execution risk and likelihood of further dilutive financing before breakeven.

Weakened Balance SheetNegative equity and a small asset base leave limited buffers against operational setbacks and constrain borrowing capacity. Meaningful reported debt relative to minimal assets elevates solvency and refinancing risk, reducing strategic flexibility and increasing the probability management must pursue dilutive capital raises.

Negative Cash FlowSustained negative operating and free cash flow means ongoing reliance on external funding to sustain R&D and commercialization. This structural funding dependency heightens execution risk, can delay product rollout timelines if capital is scarce, and exposes shareholders to dilution or restrictive financing terms.

Izotropic News

Izotropic Africa Pursues Moroccan Partnership to Advance Breast CT Expansion

The latest update is out from Izotropic ( ($TSE:IZO) ). Izotropic’s newly formed Casablanca-based venture, Izotropic Africa, is...

18d ago

Izotropic Moves to Establish African and GCC Hub for Breast CT Imaging

Izotropic ( ($TSE:IZO) ) has issued an update. Izotropic Corporation has signed a letter agreement with a business...

25d ago

Izotropic Raises Working Capital and Settles Debt with Equity Units

Izotropic ( ($TSE:IZO) ) has issued an update. Izotropic closed a $300,000 non-brokered private placement by issuing 1.2 million...

1M ago

Izotropic Plans $300,000 Private Placement to Advance IzoView Breast CT Commercialization

Izotropic ( ($TSE:IZO) ) has shared an announcement. Izotropic Corporation has provided a corporate update outlining its strategic...

2M ago

Izotropic Shareholders Approve All AGM Resolutions and Lower Quorum Threshold

Izotropic ( ($TSE:IZO) ) has provided an announcement. Izotropic Corporation reported that all resolutions presented at its Annual...

2M ago

Izotropic Corporation Announces Debt Settlement Agreement

Izotropic ( ($TSE:IZO) ) has shared an update. Izotropic Corporation has entered into a debt settlement agreement to...

3M ago

Izotropic Corporation Announces Debt Settlement Agreement

The latest announcement is out from Izotropic ( ($TSE:IZO) ). Izotropic Corporation has entered into a debt settlement...

3M ago

Izotropic Expands AI Integration in Breast Imaging with New Podcast Episode

The latest announcement is out from Izotropic ( ($TSE:IZO) ). Izotropic Corporation has released the second episode of...

4M ago

Izotropic Enhances Educational Outreach with New ‘Breast Imaging News’ Page

The latest announcement is out from Izotropic ( ($TSE:IZO) ). Izotropic Corporation has launched a ‘Breast Imaging News’...

5M ago

Izotropic Unveils Strategic Plans for IzoView Breast CT Platform

Izotropic ( ($TSE:IZO) ) has issued an announcement. Izotropic Corporation has released a video interview with CEO Bob...

5M ago

IZO FAQ

What was Izotropic Corp.’s price range in the past 12 months?

Izotropic Corp. lowest stock price was C$0.19 and its highest was C$0.49 in the past 12 months.

What is Izotropic Corp.’s market cap?

Izotropic Corp.’s market cap is C$14.91M.

When is Izotropic Corp.’s upcoming earnings report date?

Izotropic Corp.’s upcoming earnings report date is Mar 26, 2026 which is in 11 days.

How were Izotropic Corp.’s earnings last quarter?

Izotropic Corp. released its earnings results on Dec 30, 2025. The company reported -C$0.012 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.012.

Is Izotropic Corp. overvalued?

According to Wall Street analysts Izotropic Corp.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Izotropic Corp. pay dividends?

Izotropic Corp. does not currently pay dividends.

What is Izotropic Corp.’s EPS estimate?

Izotropic Corp.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Izotropic Corp. have?

Izotropic Corp. has 67,784,676 shares outstanding.

What happened to Izotropic Corp.’s price movement after its last earnings report?

Izotropic Corp. reported an EPS of -C$0.012 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.754%.

Which hedge fund is a major shareholder of Izotropic Corp.?

Currently, no hedge funds are holding shares in TSE:IZO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Izotropic Corp.

Izotropic Corporation, a MedTech company, commercializes diagnostic products for breast cancer. It develops and commercializes breast CT Imaging system; and 3D CT breast imaging platform for the earlier detection and diagnosis of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.